Looking Beyond VEGF: Why Targeting Angiopoietin-2 Can Bring Benefits

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Gemmy Cheung, MD

Professor of Ophthalmology
Duke University-NUS Medical School
University of Singapore
Senior Consultant Ophthalmologist
Singapore National Eye Center
Singapore, Republic of Singapore

Disclosures

Gemmy Cheung, MD, has the following relevant financial relationships:
Consultant or advisor for: Avirmax; Bayer; Boehringer Ingelheim; Novartis; Roche; Topcon; Zeiss
Speaker or member of speakers bureau for: Allergan; Bayer; Boehringer Ingelheim; Novartis; Roche; Topcon; Zeiss
Research funding from: Bayer; Boehringer Ingelheim; Novartis; Roche; Topcon; Zeiss
Contracted researcher for: Bayer; Boehringer Ingelheim; Novartis
Owns stock options in: Avirmax

Ramin Tadayoni, MD, PhD

Professor of Ophthalmology
Université de Paris
Head of Ophthalmology
Lariboisière, St Louis and Rothschild Foundation Hospital
Paris, France

Disclosures

Ramin Tadayoni, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Alcon; Allergan; Apellis; Bayer; Genentech; Iveric Bio; KHB; Novartis; Oculis; Thea; Roche; Zeiss
Speaker or member of speakers bureau for: AbbVie; Alcon; Allergan; Bayer; Genentech; Novartis; Roche; Zeiss
Research funding from: AbbVie; Alcon; Allergan; Bayer; Novartis; Zeiss
Stock options in: Oculis

Arshad M. Khanani, MD, MA, FARS

Clinical Associate Professor
University of Nevada, Reno School of Medicine
Director of Clinical Research
Sierra Eye Associates
Reno, Nevada, United States

Disclosures

Arshad M Khanani, MD, MA, FARS, has the following relevant financial relationships:
Consultant or advisor for: Adverum; Alimera; Allergan; Apellis; Asclepix; Aviceda; Bausch and Lomb; Broadwing Bio; Chengdu Kanghong; Cholgene; 4DMT; Dutch Ophthalmic Research Center; Gemini; Genentech; Glaukos; Graybug; Gyroscope; Iveric Bio; Janssen; Kato Pharma; Kodiak; Novartis; Oculis; Opthea; Oxurion; Polyphotonix; Recens Medical; Regeneron; Retrotope; Regenxbio; RevOpsis; Roche; Thea; Unity Bio
Speaker or member of speakers bureau for: Allergan; Genentech; Novartis
Research funding from: Adverum; Apellis; Asclepix; Chengdu Kanghong; 4DMT; Gemini; Genentech; Graybug Vision; Gyroscope; Iveric Bio; Kodiak; Neurotech; NGM Bio; Novartis; Ocular Therapeutix; Oculis; Opthea; Oxurion; Recens Medical; Regenxbio; Roche; Unity Bio
Stock options from: Aviceda; Recens Medical; Retrotope; Polyphotonix

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationships:
Advisor or consultant for: Eisai (former), GW Pharmaceuticals (former)

Compliance Reviewers

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.